Drug Approval | June 27, 2022
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Silo enters into commercial evaluation license agreement for next generation liposomes
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Brings 25 years of global operations and supply chain experience to Piramal
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated
